Table 4.
Determinants of the severity of PAKD
| Parameters | eGFR-2<60 ml/min per 1.73 m2 (n=45) | eGFR-2>60 ml/min per 1.73 m2 (n=75) | P Value |
|---|---|---|---|
| eGFR-2, ml/min per 1.73 m2 | 42.9±1.5 | 81.6±1.7 | <0.001 |
| Age, yr | 67±10 | 60±14 | 0.002 |
| Women, n (%) | 39 (88) | 55 (75) | 0.1 |
| Hypertension, n (%) | 33 (76) | 31 (44) | 0.001 |
| Diabetes, n (%) | 2 (4) | 2 (3) | 0.6 |
| Body mass index, kg/cm2 | 24±5 | 25.3±4 | 0.4 |
| Symptomatic carriers, n (%) | 40 (88) | 28 (37) | <0.001 |
| eGFR-1, ml/min per 1.73 m2 | 53.8±2.3 | 79.4±1.8 | <0.001 |
| Urine ALA-to-creatinine ratio, μmol/mmol creatinine | 5.3±0.8 | 5±0.5 | 0.6 |
| Urine PBG-to-creatinine ratio, μmol/mmol creatinine | 7.4±8.8 | 4.8±5.6 | 0.04 |
| Urine protein-to-creatinine ratio, g/mmol creatinine | 0.09±0.01 | 0.04±0.05 | 0.01 |
| PEPT2 genotype | 0.002 | ||
| *1/*1 | 17 (37) | 9 (12) | |
| *1/*2 | 23 (51) | 39 (52) | |
| *2/*2 | 5 (11) | 27 (36) |
Values are means±SD unless otherwise indicated. The GFR was estimated according to the four-variable Modification of Diet in Renal Disease formula. eGFR-1 denotes the eGFR measured in the cohort in 2003; eGFR-2 denotes the eGFR measured in the cohort in 2013. The two groups were compared using paired t test or a likelihood ratio test.